MRC/ABPI COPD Consortium Work Package 1: COPD Phenotyping

MRC/ABPI COPD 联盟工作包 1：COPD 表型分析

• 批准号: G1001365/1
• 负责人: Christopher Brightling
• 金额: $ 431.08万
• 依托单位: University of Leicester
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2011
• 资助国家: 英国
• 起止时间: 2011 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1001365%2F1
• 关键词: MRC; ABPI; COPD; Consortium; Work

COPD (which used to be called chronic bronchitis and emphysema) is a common disease which causes considerable difficulty to sufferers. The pharmaceutical industry has been relatively unsuccessful in bringing new treatments to the marketplace for COPD, with many products failing when they are first given to patients. This is largely because not all COPD sufferers are the same and it is likely that drugs will treat certain aspects of the disease and therefore are more likely to benefit some but not all patients. We propose to try to understand what makes people with COPD different from each other and to use these differences to further our understanding of which types of drugs will benefit which types of people. Using this approach we aim to identify markers in blood and sputum that will help us to predict the progression of COPD and response to therapy.

COPD（以前称为慢性支气管炎和肺气肿）是一种常见疾病，导致患者造成相当困难。制药行业在将新的治疗方法带到COPD市场方面相对不成功，当时，许多产品首次提供给患者时都会失败。这主要是因为并非所有的COPD患者都是相同的，并且药物很可能会治疗疾病的某些方面，因此更有可能受益一些但并非所有患者。我们建议试图了解是什么使患有COPD的人彼此不同，并利用这些差异来进一步了解哪种类型的药物将使哪种类型的人受益。使用这种方法，我们旨在确定血液和痰液中的标记，这将帮助我们预测COPD的进展和对治疗的反应。